EUSA, Jazz Pharmaceuticals deal

Jazz completed its acquisition of EUSA for $680 million in cash, plus a potential $50 million milestone payment tied to 2013 U.S. sales of EUSA's Erwinaze. The transaction was financed with cash and proceeds from a $475 million loan. Jazz also secured a $100 million revolving credit facility for general corporate purposes. The deal price was bumped up by $30 million from $650 million to reflect adjustments for EUSA's working capital, cash and certain liabilities (see BioCentury, April 30). ...